Do analysts recommend PYRGF or CNTB?

Connect Biopharma has a consensus target price of $7.17, indicating a potential upside of 191.33%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Do analysts rate PYRGF or GNLX?

Genelux has a consensus price target of $18.00, suggesting a potential upside of 502.01%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts recommend NRXP or PYRGF?

NRx Pharmaceuticals currently has a consensus target price of $38.25, indicating a potential upside of 888.37%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NRXP or PYRGF more profitable?

NRx Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% PyroGenesis Canada -115.14% N/A -60.81%

Do analysts prefer PYRGF or COYA?

Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 161.66%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Do analysts rate CRDL or PYRGF?

Cardiol Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 709.52%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

PyroGenesis Canada (PYRGF) Competitors

$0.14 +0.00 (+0.14%)

As of 07/2/2026 03:51 PM Eastern

Compare

PYRGF vs. CNTB, GNLX, NRXP, COYA, and CRDL

Should you buy PyroGenesis Canada stock or one of its competitors? MarketBeat compares PyroGenesis Canada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PyroGenesis Canada include Connect Biopharma (CNTB), Genelux (GNLX), NRx Pharmaceuticals (NRXP), Coya Therapeutics (COYA), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry.

How does PyroGenesis Canada compare to Connect Biopharma?

PyroGenesis Canada (NASDAQ:PYRGF) and Connect Biopharma (NASDAQ:CNTB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

PyroGenesis Canada has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Connect Biopharma. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A
Connect Biopharma	$60K	2,581.36	-$55.48M	-$1.15	N/A

In the previous week, Connect Biopharma had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 1 mentions for Connect Biopharma and 0 mentions for PyroGenesis Canada. PyroGenesis Canada's average media sentiment score of 0.00 beat Connect Biopharma's score of -0.17 indicating that PyroGenesis Canada is being referred to more favorably in the media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Connect Biopharma	Neutral

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Connect Biopharma has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Connect Biopharma	N/A	-122.29%	-97.07%

Connect Biopharma has a consensus target price of $7.17, indicating a potential upside of 191.33%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Connect Biopharma beats PyroGenesis Canada on 9 of the 17 factors compared between the two stocks.

How does PyroGenesis Canada compare to Genelux?

PyroGenesis Canada (NASDAQ:PYRGF) and Genelux (NASDAQ:GNLX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Genelux has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Genelux	N/A	-174.55%	-123.65%

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genelux has a consensus price target of $18.00, suggesting a potential upside of 502.01%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

PyroGenesis Canada has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Genelux has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Genelux. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A
Genelux	$10K	13,407.16	-$32.15M	-$0.85	N/A

In the previous week, Genelux had 4 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for Genelux and 0 mentions for PyroGenesis Canada. Genelux's average media sentiment score of 0.20 beat PyroGenesis Canada's score of 0.00 indicating that Genelux is being referred to more favorably in the news media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Genelux	Neutral

Summary

Genelux beats PyroGenesis Canada on 9 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NRx Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than NRx Pharmaceuticals. PyroGenesis Canada is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	113.99	-$28.62M	-$1.09	N/A
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A

In the previous week, NRx Pharmaceuticals' average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
PyroGenesis Canada	Neutral

NRx Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
PyroGenesis Canada	-115.14%	N/A	-60.81%

NRx Pharmaceuticals currently has a consensus target price of $38.25, indicating a potential upside of 888.37%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

NRx Pharmaceuticals beats PyroGenesis Canada on 7 of the 13 factors compared between the two stocks.

How does PyroGenesis Canada compare to Coya Therapeutics?

PyroGenesis Canada (NASDAQ:PYRGF) and Coya Therapeutics (NASDAQ:COYA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Coya Therapeutics had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 1 mentions for Coya Therapeutics and 0 mentions for PyroGenesis Canada. Coya Therapeutics' average media sentiment score of 0.50 beat PyroGenesis Canada's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Coya Therapeutics	Positive

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 161.66%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

PyroGenesis Canada has a net margin of -115.14% compared to Coya Therapeutics' net margin of -266.10%. PyroGenesis Canada's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

PyroGenesis Canada has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A
Coya Therapeutics	$7.95M	17.29	-$21.23M	-$1.15	N/A

Summary

Coya Therapeutics beats PyroGenesis Canada on 9 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Cardiol Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
PyroGenesis Canada	-115.14%	N/A	-60.81%

PyroGenesis Canada has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A

Cardiol Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
PyroGenesis Canada	Neutral

Cardiol Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 709.52%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

PyroGenesis Canada beats Cardiol Therapeutics on 7 of the 13 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYRGF vs. The Competition

Export

Metric	PyroGenesis Canada	Pharmaceutical Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$32.51M	$791.45M	$9.60B	$12.48B
Dividend Yield	N/A	4.84%	3.53%	6.52%
P/E Ratio	-2.41	1.66	27.03	24.70
Price / Sales	3.56	127.11	4,750.02	99.49
Price / Cash	N/A	20.06	27.49	57.09
Price / Book	-14.44	8.17	4.60	6.46
Net Income	-$21.12M	-$3.71M	$791.01M	$337.01M
7 Day Performance	-0.14%	2.59%	0.96%	1.69%
1 Month Performance	-17.95%	4.41%	0.95%	3.81%
1 Year Performance	-57.64%	49.43%	18.47%	23.90%

PyroGenesis Canada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYRGF PyroGenesis Canada	N/A	$0.14 +0.1%	N/A	-57.6%	$32.51M	$9.14M	N/A	90	Gap Up
CNTB Connect Biopharma	4.5067 of 5 stars	$2.21 +6.5%	$7.17 +225.0%	+116.7%	$130.34M	$233K	N/A	110	Analyst Downgrade Gap Up High Trading Volume
GNLX Genelux	1.895 of 5 stars	$2.87 -0.9%	$18.00 +526.5%	+0.3%	$130.04M	$10K	N/A	10	News Coverage Gap Up High Trading Volume
NRXP NRx Pharmaceuticals	2.2614 of 5 stars	$3.73 +4.8%	$38.25 +925.5%	+16.9%	$128.98M	$2.29M	N/A	2
COYA Coya Therapeutics	2.3879 of 5 stars	$5.50 +7.2%	$15.33 +178.8%	-6.5%	$120.33M	$7.95M	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYRGF) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. CNTB, GNLX, NRXP, COYA, and CRDL

How does PyroGenesis Canada compare to Connect Biopharma?

Summary

How does PyroGenesis Canada compare to Genelux?

Summary

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

Summary

How does PyroGenesis Canada compare to Coya Therapeutics?

Summary

How does PyroGenesis Canada compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. CNTB, GNLX, NRXP, COYA, and CRDL

How does PyroGenesis Canada compare to Connect Biopharma?

Which has more risk & volatility, PYRGF or CNTB?

Which has preferable valuation & earnings, PYRGF or CNTB?

Does the media prefer PYRGF or CNTB?

Do institutionals and insiders believe in PYRGF or CNTB?

Is PYRGF or CNTB more profitable?

Do analysts recommend PYRGF or CNTB?

Summary

How does PyroGenesis Canada compare to Genelux?

Is PYRGF or GNLX more profitable?

Do institutionals and insiders hold more shares of PYRGF or GNLX?

Do analysts rate PYRGF or GNLX?

Which has more risk and volatility, PYRGF or GNLX?

Which has better earnings & valuation, PYRGF or GNLX?

Does the media prefer PYRGF or GNLX?

Summary

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

Do insiders and institutionals hold more shares of NRXP or PYRGF?

Which has more volatility & risk, NRXP or PYRGF?

Which has higher earnings & valuation, NRXP or PYRGF?

Does the media refer more to NRXP or PYRGF?

Is NRXP or PYRGF more profitable?

Do analysts recommend NRXP or PYRGF?

Summary

How does PyroGenesis Canada compare to Coya Therapeutics?

Does the media prefer PYRGF or COYA?

Do institutionals & insiders believe in PYRGF or COYA?

Do analysts prefer PYRGF or COYA?

Is PYRGF or COYA more profitable?

Which has more volatility & risk, PYRGF or COYA?

Which has stronger valuation and earnings, PYRGF or COYA?

Summary

How does PyroGenesis Canada compare to Cardiol Therapeutics?

Is CRDL or PYRGF more profitable?

Which has stronger earnings and valuation, CRDL or PYRGF?

Which has more volatility and risk, CRDL or PYRGF?

Does the media refer more to CRDL or PYRGF?

Do analysts rate CRDL or PYRGF?

Do insiders and institutionals have more ownership in CRDL or PYRGF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools